Development and GC-MS validation of a highly sensitive recombinant G6PDH-based homogeneous immunoassay for the detection of buprenorphine and norbuprenorphine in urine.

@article{Wang2007DevelopmentAG,
  title={Development and GC-MS validation of a highly sensitive recombinant G6PDH-based homogeneous immunoassay for the detection of buprenorphine and norbuprenorphine in urine.},
  author={Guohong Wang and Michael J Vincent and Warren C Rodrigues and Alpana Agrawal and Christine Moore and Rekha N Barhate and E Abolencia and Cynthia Coulter and James R Soares and Yi-Feng Zheng and Celeste Taylor and Nihmat Morjana},
  journal={Journal of analytical toxicology},
  year={2007},
  volume={31 7},
  pages={377-82}
}
Buprenorphine is now increasingly prescribed as an alternative to methadone for the treatment of heroin addiction. Because of its potency (dosage usages from 0.2 mg to 8 mg), the drug concentrations in body fluids are normally very low. Here, we report the first recombinant glucose-6-phosphate dehydrogenase (G6PDH)-based homogeneous immunoassay (EMIT-type assay) for free buprenorphine and free norbuprenorphine in urine. The antibody used in this assay cross-reacts nearly identically with… CONTINUE READING